33 results on '"McMurray, John J.V."'
Search Results
2. Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin: A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)
- Author
-
Cleland, John G.F., McMurray, John J.V., Kjekshus, John, Cornel, Jan H., Dunselman, Peter, Fonseca, Cândida, Hjalmarson, Åke, Korewicki, Jerzy, Lindberg, Magnus, Ranjith, Naresh, van Veldhuisen, Dirk J., Waagstein, Finn, Wedel, Hans, and Wikstrand, John
- Subjects
- *
CHRONIC kidney failure , *HEART failure patients , *CARDIOVASCULAR agents , *CORONARY disease , *PLACEBOS , *MYOCARDIAL infarction , *RANDOMIZED controlled trials , *PATIENTS - Abstract
Objectives: We investigated whether plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP), a marker of cardiac dysfunction and prognosis measured in CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure), could be used to identify the severity of heart failure at which statins become ineffective. Background: Statins reduce cardiovascular morbidity and mortality in many patients with ischemic heart disease but not, overall, those with heart failure. There must be a transition point at which treatment with a statin becomes futile. Methods: In CORONA, patients with heart failure, reduced left ventricular ejection fraction, and ischemic heart disease were randomly assigned to 10 mg/day rosuvastatin or placebo. The primary composite outcome was cardiovascular death, nonfatal myocardial infarction, or stroke. Results: Of 5,011 patients enrolled, NT-proBNP was measured in 3,664 (73%). The midtertile included values between 103 pmol/l (868 pg/ml) and 277 pmol/l (2,348 pg/ml). Log NT-proBNP was the strongest predictor (per log unit) of every outcome assessed but was strongest for death from worsening heart failure (hazard ratio [HR]: 1.99; 95% confidence interval [CI]: 1.71 to 2.30), was weaker for sudden death (HR: 1.69; 95% CI: 1.52 to 1.88), and was weakest for atherothrombotic events (HR: 1.24; 95% CI: 1.10 to 1.40). Patients in the lowest tertile of NT-proBNP had the best prognosis and, if assigned to rosuvastatin rather than placebo, had a greater reduction in the primary end point (HR: 0.65; 95% CI: 0.47 to 0.88) than patients in the other tertiles (heterogeneity test, p = 0.0192). This reflected fewer atherothrombotic events and sudden deaths with rosuvastatin. Conclusions: Patients with heart failure due to ischemic heart disease who have NT-proBNP values <103 pmol/l (868 pg/ml) may benefit from rosuvastatin. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
3. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
- Author
-
Wamil, Malgorzata, McMurray, John J.V., Scott, Charles A.B., Coleman, Ruth L., Sun, Yihong, Standl, Eberhard, Rydén, Lars, and Holman, Rury R.
- Subjects
- *
CORONARY disease , *HEART failure patients , *CARDIAC patients , *HEART failure , *TYPE 2 diabetes , *ACARBOSE , *GLUCOSE intolerance , *MYOCARDIAL infarction , *DISEASE incidence , *TREATMENT effectiveness , *GLYCOSIDASES , *PROPORTIONAL hazards models , *CREATININE , *CHEMICAL inhibitors ,MYOCARDIAL infarction-related mortality - Abstract
Aims: Heart failure is a fatal complication of type 2 diabetes but little is known about its incidence in people with impaired glucose tolerance (IGT). We used Acarbose Cardiovascular Evaluation (ACE) trial data to identify predictors of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in patients with coronary heart disease (CHD) and IGT randomised to acarbose or placebo.Methods: Independent hHF/CV death risk factors were determined using Cox proportional hazards models, with participants censored at first hHF event, CV death, or end of follow-up.Results: During median 5-year follow-up, the composite outcome of hHF/CV death occurred in 393 (6.0%) participants. Significant hHF/CV death multivariate predictors were higher age and plasma creatinine, and prior heart failure (HF), myocardial infarction (MI), atrial fibrillation (AF) and stroke. Acarbose, compared with placebo, did not reduce hHF/CV death (hazard ratio [HR] 0.89, 95% CI 0.64-1.24, P = 0.48) or hHF (HR 0.90, 95% CI 0.74-1.10, P = 0.32).Conclusions: Patients with CHD and IGT at greater risk of hHF/CV death were older with higher plasma creatinine, prior HF, MI, AF or stroke. Addition of acarbose to optimised CV therapy to reduce post-prandial glucose excursions did not reduce the risk of hHF/CV death or hHF.Clinical Trial Registration: ClinicalTrials.gov, number NCT00829660, and the International Standard Randomised Controlled Trial Number registry, number ISRCTN91899513. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
4. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function.
- Author
-
Matsumoto, Shingo, Henderson, Alasdair D., Shen, Li, Yang, Mingming, Swedberg, Karl, Vaduganathan, Muthiah, van Veldhuisen, Dirk J., Solomon, Scott D., Pitt, Bertram, Zannad, Faiez, Jhund, Pardeep S., and McMurray, John J.V.
- Subjects
- *
MINERALOCORTICOID receptors , *HEART failure patients , *KIDNEY physiology , *KIDNEY failure , *TERMINATION of treatment - Abstract
Kidney dysfunction often leads to reluctance to start or continue life-saving heart failure (HF) therapy. This study sought to examine the efficacy and safety of mineralocorticoid receptor antagonists (MRAs) in patients with HF with reduced ejection fraction experiencing significant kidney dysfunction. We pooled individual patient data from the RALES (Randomized Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trials. The association between MRA treatment and outcomes was assessed according to whether the estimated glomerular filtration rate (eGFR) declined to <30 mL/min/1.73 m2 or not. The primary outcome was cardiovascular death or HF hospitalization. Among 4,355 patients included, 295 (6.8%) experienced a deterioration of eGFR after randomization to <30 mL/min/1.73 m2. These patients had more impaired baseline cardiac and kidney function (eGFR 47.3 ± 13.4 mL/min/1.73 m2 vs 70.5 ± 21.8 mL/min/1.73 m2) and had a higher risk of the primary outcome than patients without eGFR deterioration (HR: 2.49; 95% CI: 2.01-3.08; P < 0.001). However, the risk reduction in the primary outcome with MRA therapy was similar in those who experienced a decrease in eGFR to <30 mL/min/1.73 m2 (HR: 0.65; 95% CI: 0.43-0.99) compared with those who did not (HR: 0.63; 95% CI: 0.56-0.71) (P interaction = 0.87). In patients with a decrease in eGFR to <30 mL/min/1.73 m2, 21 fewer individuals (per 100 person-years) experienced the primary outcome with MRA treatment, vs placebo, compared with an excess of 3 more patients with severe hyperkalemia (>6.0 mmol/L). Because patients experiencing a decrease in eGFR to <30 mL/min/1.73 m2 are at very high risk, the absolute risk reduction with an MRA in these patients is large and this decline in eGFR should not automatically lead to treatment discontinuation. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
- Author
-
Chatur, Safia, Neuen, Brendon L., Claggett, Brian L., Beldhuis, Iris E., Mc Causland, Finnian R., Desai, Akshay S., Rouleau, Jean L., Zile, Michael R., Lefkowitz, Martin P., Packer, Milton, McMurray, John J.V., Solomon, Scott D., and Vaduganathan, Muthiah
- Subjects
- *
HEART failure , *HEART failure patients , *ENTRESTO , *VALSARTAN , *CHRONIC kidney failure , *GLOMERULAR filtration rate - Abstract
The Kidney Disease Improving Global Outcomes (KDIGO) classification integrates both estimated glomerular filtration rate and urine-albumin-creatinine ratio to stratify risk more comprehensively in patients with chronic kidney disease. There are limited data assessing whether this classification system is associated with prognosis and treatment response in heart failure populations. The aim of this study was to evaluate the relative treatment effects of sacubitril/valsartan across the KDIGO risk categories in patients with HFrEF. PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) was a global randomized controlled trial evaluating sacubitril/valsartan vs enalapril in patients with heart failure with reduced ejection fraction (HFrEF). Patients were classified according to low, moderate, and high/very high KDIGO risk. Treatment responses were assessed according to baseline KDIGO risk. The primary outcome was a composite of cardiovascular (CV) death or heart failure hospitalization. A renal composite outcome was defined as sustained decline in estimated glomerular filtration rate by ≥40% or end-stage kidney disease. Among 1,910 (23% of total) participants with available data, 42%, 32%, and 26% were classified as low, moderate, and high/very high KDIGO risk, respectively. Patients in the highest KDIGO risk categories experienced the highest rates of the primary composite outcome (7.6 per 100 person-years [95% CI: 6.5-9.0 per 100 person-years], 9.4 per 100 person-years [95% CI: 7.9-11.2 per 100 person-years], and 14.9 per 100 person-years [95% CI: 12.7-17.6 per 100 person-years]; P < 0.001). Sacubitril/valsartan had a similar safety profile and demonstrated consistent effects on the risk of both the primary outcome (P Interaction = 0.31) and the renal composite outcome (P Interaction = 0.50) across the spectrum of KDIGO risk. One in 4 patients with HFrEF were classified as at least high KDIGO kidney risk; these individuals faced concordantly the highest risks of CV events. Sacubitril/valsartan exhibited consistent CV and kidney protective benefits as well as safety across the spectrum of baseline kidney risk. These data further support initiation of sacubitril/valsartan in HFrEF across a broad range of kidney risk. (This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure [PARADIGM-HF]; NCT01035255) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial.
- Author
-
Kondo, Toru, Mogensen, Ulrik M., Talebi, Atefeh, Gasparyan, Samvel B., Campbell, Ross T., Docherty, Kieran F., de Boer, Rudolf A., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Sabatine, Marc S., Bengtsson, Olof, Sjöstrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.
- Subjects
- *
DAPAGLIFLOZIN , *VENTRICULAR ejection fraction , *HEART failure patients , *HEART failure ,CARDIOVASCULAR disease related mortality - Abstract
Conventional time-to-first-event analyses cannot incorporate recurrent hospitalizations and patient well-being in a single outcome. To overcome this limitation, we tested an integrated measure that includes days lost from death and hospitalization, and additional days of full health lost through diminished well-being. The effect of dapagliflozin on this integrated measure was assessed in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial, which examined the efficacy of dapagliflozin, compared with placebo, in patients with NYHA functional class II to IV heart failure and a left ventricular ejection fraction ≤40%. Over 360 days, patients in the dapagliflozin group (n = 2,127) lost 10.6 ± 1.0 (2.9%) of potential follow-up days through cardiovascular death and heart failure hospitalization, compared with 14.4 ± 1.0 days (4.0%) in the placebo group (n = 2,108), and this component of all measures of days lost accounted for the greatest between-treatment difference (−3.8 days [95% CI: −6.6 to −1.0 days]). Patients receiving dapagliflozin also had fewer days lost to death and hospitalization from all causes vs placebo (15.5 ± 1.1 days [4.3%] vs 20.3 ± 1.1 days [5.6%]). When additional days of full health lost (ie, adjusted for Kansas City Cardiomyopathy Questionnaire–overall summary score) were added, total days lost were 110.6 ± 1.6 days (30.7%) with dapagliflozin vs 116.9 ± 1.6 days (32.5%) with placebo. The difference in all measures between the 2 groups increased over time (ie, days lost by death and hospitalization −0.9 days [−0.7%] at 120 days, −2.3 days [−1.0%] at 240 days, and −4.8 days [−1.3%] at 360 days). Dapagliflozin reduced the total days of potential full health lost due to death, hospitalizations, and impaired well-being, and this benefit increased over time during the first year. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure; NCT03036124) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
- Author
-
Foà, Alberto, Vaduganathan, Muthiah, Claggett, Brian L., Pabon, Maria A., Lu, Henri, Pfeffer, Marc A., Packer, Milton, Vardeny, Orly, Rouleau, Jean L., Lefkowitz, Martin, Mentz, Robert J., Jhund, Pardeep S., Desai, Akshay S., McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
HEART failure , *HEART failure patients , *VENTRICULAR ejection fraction , *HYPOTENSION , *SYSTOLIC blood pressure , *POISSON regression ,CARDIOVASCULAR disease related mortality - Abstract
Hypotension is a potential adverse effect of sacubitril/valsartan, but there are limited data regarding the predictors and implications of treatment-related hypotension in heart failure (HF) with mildly reduced and preserved ejection fraction. We investigated predictors of treatment-associated hypotension, clinical outcomes after hypotension, and the relationship between left ventricular ejection fraction (LVEF) and incidence of hypotension in the PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) trial. PARAGON-HF randomized patients with chronic HF (≥45%) to sacubitril/valsartan or valsartan. Following randomization, hypotension was defined as investigator-reported hypotension with a systolic blood pressure <100 mm Hg. Predictors of hypotension were assessed using multivariable Cox models. Associations between hypotension and clinical outcomes were evaluated in time-updated Cox models. The relationship among treatment, LVEF, and incident rates of hypotension and clinical outcomes was estimated using Poisson regression models. Of 4,796 patients in PARAGON-HF, 637 (13%) experienced hypotension, more frequently in the sacubitril/valsartan arm (P < 0.001). Following documented hypotension, patients had higher risk of cardiovascular death and total HF hospitalizations (adjusted RR: 1.63; 95% CI: 1.27-2.09; P < 0.001) and all-cause death (adjusted HR: 1.62; 95% CI: 1.28-2.05; P < 0.001). LVEF modified the association between sacubitril/valsartan and risk of hypotension (P interaction = 0.019) such that patients with LVEF ≥60% experienced substantially higher treatment-related risks of hypotension. In PARAGON-HF, a higher LVEF was associated with an increased risk of hypotension in patients treated with sacubitril/valsartan compared with valsartan. Because these subjects are also less likely to derive clinical benefit from sacubitril/valsartan, our data reinforce that the benefit/risk ratio favors the use of sacubitril/valsartan in patients with LVEF below normal, but not at higher LVEF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.
- Author
-
Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian L., Mc Causland, Finnian R., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe A., Shah, Sanjiv J., Sabatine, Marc S., Kober, Lars, Ponikowski, Piotr, Merkely, Bela, Petersson, Magnus, Langkilde, Anna Maria, and McMurray, John J.V.
- Subjects
- *
HEART failure patients , *DAPAGLIFLOZIN , *KIDNEY physiology , *PROPORTIONAL hazards models , *KIDNEY failure - Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are guideline recommended in the management of heart failure (HF). Although these therapies can be initiated even in patients with comorbid chronic kidney disease, some patients may face deterioration of kidney function over time. In this study, the authors sought to examine the safety and efficacy of continuing SGLT2 inhibitors in HF when the estimated glomerular filtration rate (eGFR) falls below thresholds for initiation. Associations between a deterioration of eGFR to <25 mL/min/1.73 m2, efficacy, and safety outcomes and treatment with dapagliflozin were evaluated in time-updated Cox proportional hazard models in a participant-level pooled analysis of the DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trials. Among 11,007 patients, 347 (3.2%) experienced a deterioration of eGFR to <25 mL/min/1.73 m2 at least once in follow-up. These patients had a higher risk of the primary composite outcome (HR: 1.87; 95% CI: 1.48-2.35; P < 0.001). The risk of the primary outcome was lower with dapagliflozin compared with placebo among patients who did (HR: 0.53; 95% CI: 0.33-0.83) as well as did not (HR: 0.78; 95% CI: 0.72-0.86) experience deterioration of eGFR to <25 mL/min/1.73 m2 (P interaction = 0.17). The risk of safety outcomes, including drug discontinuation, was higher among patients with deterioration of eGFR to <25 mL/min/1.73 m2; however, rates remained similar between treatment groups including among those who remained on study drug. Patients with deterioration of eGFR to <25 mL/min/1.73 m2 had elevated risks of cardiovascular outcomes yet appeared to benefit from continuation of dapagliflozin with no excess in safety outcomes between treatment groups. The benefit-to-risk ratio may favor continuation of dapagliflozin treatment in patients with HF experiencing deterioration of kidney function. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124 ; and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction.
- Author
-
Matsumoto, Shingo, Kondo, Toru, Jhund, Pardeep S., Campbell, Ross T., Swedberg, Karl, van Veldhuisen, Dirk J., Pocock, Stuart J., Pitt, Bertram, Zannad, Faiez, and McMurray, John J.V.
- Subjects
- *
HEART failure patients , *VENTRICULAR ejection fraction , *MINERALOCORTICOID receptors - Published
- 2023
- Full Text
- View/download PDF
10. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction.
- Author
-
Inciardi, Riccardo M., Abanda, Martin, Shah, Amil M., Cikes, Maja, Claggett, Brian, Skali, Hicham, Vaduganathan, Muthiah, Prasad, Narayana, Litwin, Sheldon, Merkely, Bela, Kosztin, Annamaria, Nagy, Klaudia Vivien, Shah, Sanjiv J., Mullens, Wilfred, Zile, Michael R., Lam, Carolyn S.P., Pfeffer, Marc A., McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
BRAIN natriuretic factor , *HEART failure patients , *VENTRICULAR ejection fraction , *PULMONARY circulation , *SYSTOLIC blood pressure - Abstract
Limited data exist to characterize novel measures of right ventricular (RV) function and the coupling to pulmonary circulation in patients with heart failure and preserved left ventricular ejection fraction (HFpEF). This study sought to assess the clinical implications of RV function, the association with N-terminal pro–B-type natriuretic peptide, and the risk for adverse events among patients with HFpEF. This study analyzed measures of RV function by assessing absolute RV free wall longitudinal strain (RVFWLS) and its ratio to estimated pulmonary artery systolic pressure (PASP) (RVFWLS/PASP ratio) in 528 patients (mean age 74 ± 8 years, 56% female) with adequate echocardiographic images quality enrolled in the PARAGON-HF trial. Associations with baseline N-terminal pro–B-type natriuretic peptide and with total HF hospitalizations and cardiovascular death were assessed, after accounting for confounders. Overall, 311 patients (58%) had evidence of RV dysfunction, defined as absolute RVFWLS <20%, and among the 388 patients (73%) with normal tricuspid annular planar systolic excursion and RV fractional area change, more than one-half showed impaired RV function. Lower values of RVFWLS and RVFWLS/PASP ratios were significantly associated with higher circulating N-terminal pro–B-type natriuretic peptide. With a median follow-up of 2.8 years, there were 277 total HF hospitalizations and cardiovascular deaths. Both absolute RVFWLS (HR: 1.39; 95% CI: 1.05-1.83; P = 0.018) and RVFWLS/PASP ratio (HR: 1.43; 95% CI: 1.13-1.80; P = 0.002) were significantly associated with the composite outcome. Treatment effect of sacubitril/valsartan was not modified by measures of RV function. Worsening RV function and its ratio to pulmonary pressure is common and significantly associated with an increased risk of HF hospitalizations and cardiovascular death in patients with HFpEF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Global Comparison of Readmission Rates for Patients With Heart Failure.
- Author
-
Foroutan, Farid, Rayner, Daniel G., Ross, Heather J., Ehler, Tamara, Srivastava, Ananya, Shin, Sheojung, Malik, Abdullah, Benipal, Harsukh, Yu, Clarissa, Alexander Lau, Tsz Hin, Lee, Joshua G., Rocha, Rodolfo, Austin, Peter C., Levy, Daniel, Ho, Jennifer E., McMurray, John J.V., Zannad, Faiez, Tomlinson, George, Spertus, John A., and Lee, Douglas S.
- Subjects
- *
HEART failure patients , *PATIENT readmissions , *HEART beat - Published
- 2023
- Full Text
- View/download PDF
12. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
- Author
-
Chatur, Safia, Claggett, Brian L., McCausland, Finnian R., Rouleau, Jean, Zile, Michael R., Packer, Milton, Pfeffer, Marc A., Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D., and Vaduganathan, Muthiah
- Subjects
- *
HEART failure patients , *KIDNEY physiology , *VALSARTAN , *ENTRESTO , *ACE inhibitors - Abstract
Some patients with heart failure may experience transient changes in kidney function upon transition to sacubitril/valsartan. Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan continuation is unknown. This investigation aimed to evaluate the association between the occurrence of moderate estimated glomerular filtration rate (eGFR) decline (>15%) after initial exposure to sacubitril/valsartan and subsequent cardiovascular outcomes and its treatment benefits in PARADIGM-HF and PARAGON-HF. In sequential run-in phases, patients were titrated to enalapril 10 mg twice daily and then sacubitril/valsartan 97 mg/103 mg twice daily (in PARADIGM-HF) or valsartan 80 mg twice daily and then sacubitril/valsartan 49 mg/51 mg twice daily (in PARAGON-HF). Among randomized participants, 11% in PARADIGM-HF and 10% in PARAGON-HF experienced eGFR decline (>15%) during sacubitril/valsartan run-in. eGFR partially recovered (from nadir to postrandomization week 16) regardless of sacubitril/valsartan continuation or switch to renin-angiotensin system inhibitor (RASi) postrandomization. Initial eGFR decline was not consistently associated with clinical outcomes in either trial. Treatment benefits of sacubitril/valsartan vs RASi on primary outcomes were similar irrespective of run-in eGFR decline in PARADIGM-HF (eGFR decline, HR: 0.69; 95% CI: 0.53-0.90; and no eGFR decline, HR: 0.80; 95% CI: 0.73-0.88; P interaction = 0.32) and PARAGON-HF (eGFR decline, rate ratio [RR]: 0.84; 95% CI: 0.52-1.36 and no eGFR decline, RR: 0.87; 95% CI: 0.75-1.02, P interaction = 0.92). The treatment effect of sacubitril/valsartan remained consistent across a range of eGFR declines. Moderate eGFR decline when transitioning from RASi to sacubitril/valsartan is not consistently associated with adverse outcomes, and its long-term benefits are retained in heart failure across a broad range of eGFR declines. Early eGFR changes should not deter continuation of sacubitril/valsartan or stall uptitration. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711 ; Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitors with Angiotensin-Converting Enzyme Inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Dapagliflozin and All-Cause Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction.
- Author
-
Vaduganathan, Muthiah, Claggett, Brian L., Jhund, Pardeep, Miao, Zi Michael, de Boer, Rudolf A., Lam, Carolyn S.P., Desai, Akshay S., Bengsston, Olof, McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
HEART failure patients , *VENTRICULAR ejection fraction , *DAPAGLIFLOZIN , *HOSPITAL care - Published
- 2023
- Full Text
- View/download PDF
14. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.
- Author
-
Fiuzat, Mona, Hamo, Carine E., Butler, Javed, Abraham, William T., DeFilippis, Ersilia M., Fonarow, Gregg C., Lindenfeld, Joann, Mentz, Robert J., Psotka, Mitchell A., Solomon, Scott D., Teerlink, John R., Vaduganathan, Muthiah, Vardeny, Orly, McMurray, John J.V., and O'Connor, Christopher M.
- Subjects
- *
HEART failure patients , *CLINICAL trials , *MEDICAL research personnel , *DRUG therapy , *VENTRICULAR ejection fraction - Abstract
With the current landscape of approved therapies for heart failure (HF), there is a need to determine the role of a standard background therapy against which novel therapies are studied. The Heart Failure Collaboratory convened a multistakeholder group of clinical investigators, clinicians, patients, government representatives including U.S. Food and Drug Administration and National Institutes of Health participants, payers, and industry in March 2021 to discuss whether standardization of background drug therapy is necessary in clinical trials in patients with HF. The current paper summarizes the discussion and provides potential conceptual approaches, with a focus on therapies indicated for HF with reduced ejection fraction. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.
- Author
-
Teerlink, John R., Diaz, Rafael, Felker, G. Michael, McMurray, John J.V., Metra, Marco, Solomon, Scott D., Biering-Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Fang, James C., Lanfear, David E., Lund, Mayanna, Momomura, Shin-ichi, O'Meara, Eileen, Ponikowski, Piotr, Spinar, Jindrich, Flores-Arredondo, Jose H., Claggett, Brian L., Heitner, Stephen B., and Kupfer, Stuart
- Subjects
- *
TREATMENT effectiveness , *HEART failure patients , *HEART failure , *CONFIDENCE intervals , *RESEARCH , *UREA , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *STROKE volume (Cardiac output) ,CARDIOVASCULAR disease related mortality - Abstract
Background: In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure) (n = 8,256), the cardiac myosin activator, omecamtiv mecarbil, significantly reduced the primary composite endpoint (PCE) of time-to-first heart failure event or cardiovascular death in patients with heart failure and reduced ejection fraction (EF) (≤35%).Objectives: The purpose of this study was to evaluate the influence of baseline EF on the therapeutic effect of omecamtiv mecarbil.Methods: Outcomes in patients treated with omecamtiv mecarbil were compared with placebo according to EF.Results: The risk of the PCE in the placebo group was nearly 1.8-fold greater in the lowest EF (≤22%) compared with the highest EF (≥33%) quartile. Amongst the pre-specified subgroups, EF was the strongest modifier of the treatment effect of omecamtiv mecarbil on the PCE (interaction as continuous variable, p = 0.004). Patients receiving omecamtiv mecarbil had a progressively greater relative and absolute treatment effect as baseline EF decreased, with a 17% relative risk reduction for the PCE in patients with baseline EF ≤22% (n = 2,246; hazard ratio: 0.83; 95% confidence interval: 0.73 to 0.95) compared with patients with EF ≥33% (n = 1,750; hazard ratio: 0.99; 95% confidence interval: 0.84 to 1.16; interaction as EF by quartiles, p = 0.013). The absolute reduction in the PCE increased with decreasing EF (EF ≤22%; absolute risk reduction, 7.4 events per 100 patient-years; number needed to treat for 3 years = 11.8), compared with no reduction in the highest EF quartile.Conclusions: In heart failure patients with reduced EF, omecamtiv mecarbil produced greater therapeutic benefit as baseline EF decreased. These findings are consistent with the drug's mechanism of selectively improving systolic function and presents an important opportunity to improve the outcomes in a group of patients at greatest risk. (Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction [GALACTIC-HF]; NCT02929329). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
- Author
-
Hsiao, Fu-Chih, Lin, Chia-Pin, Tung, Ying-Chang, Chang, Po-Cheng, McMurray, John J.V., and Chu, Pao-Hsien
- Subjects
- *
SODIUM-glucose cotransporter 2 inhibitors , *HEART failure patients , *SODIUM-glucose cotransporters , *DIABETES , *ALDOSTERONE antagonists , *ANGIOTENSINS , *TYPE 2 diabetes - Abstract
Few studies investigated the combination of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and angiotensin receptor-neprilysin inhibitors (ARNIs) in patients with heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM). During 2016 to 2018, patients with HFrEF and T2DM were identified from Chang Gung Research Database; a database deriving from the original electronic medical records of 7 hospitals in Taiwan. They were classified into four subgroups according to the medications received as follows: 1) SGLT2i and ARNI; 2) SGLT2i and no ARNI; 3) ARNI and no SGLT2i; and 4) no SGLT2i and no ARNI. We examined clinical and safety (hyperkalemia and acute renal dysfunction) outcomes over 1-year of follow-up. A total of 2312 patients were eligible for analysis, including 169, 285, 338, and 1520 in subgroups 1, 2, 3 and 4, respectively. There were large differences in baseline characteristics and treatments among subgroups. Subgroup 1 had the lowest rates of HF hospitalizations, all-cause death, and the composite of both, and subgroup 4 had the highest event rates. A similar pattern was observed for the safety outcomes. These differences were attenuated after adjusting for differences in baseline variables and therapy. Treatment with a combination of SGLT2i and ARNI was well tolerated in diabetic patients with HFrEF and was associated with lower risk of heart failure hospitalization. • Few studies investigated the combination of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and angiotensin receptor-neprilysin inhibitors (ARNIs) in patients with heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM). • A total of 2312 patients were eligible for analysis. • Treatment with a combination of SGLT2i and ARNI was well tolerated in HFrEF patients with T2DM, and was associated with favourable cardiovascular outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. EFFECTS OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF KIDNEY RISK.
- Author
-
Chatur, Safia, Claggett, Brian, Causland, Finnian Mc, Packer, Milton, Desai, Akshay S., Rouleau, Jean L., Zile, Michael R., Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D., and Vaduganathan, Muthiah
- Subjects
- *
HEART failure patients , *ENTRESTO , *VALSARTAN , *KIDNEYS - Published
- 2024
- Full Text
- View/download PDF
18. PREDICTORS AND PROGNOSIS OF INCIDENT POOR NUTRITIONAL STATUS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: INSIGHTS FROM THE PARAGON-HF TRIAL.
- Author
-
Lu, Henri, Claggett, Brian, Minamisawa, Masatoshi, Karabay, Arzu Kalayci, Seidelmann, Sara Bretschger, Ostrominski, John, Lee, Sahmin, Foà, Alberto, Desai, Akshay S., Shah, Amil M., Pfeffer, Marc A., McMurray, John J.V., Hegde, Sheila M., Solomon, Scott D., and Skali, Hicham
- Subjects
- *
HEART failure , *NUTRITIONAL status , *HEART failure patients , *VENTRICULAR ejection fraction , *PROGNOSIS - Published
- 2024
- Full Text
- View/download PDF
19. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL.
- Author
-
Vaduganathan, Muthiah, Claggett, Brian, Kulac, Ian, Johansen, Niklas Dyrby, Reza, Nosheen, Jhund, Pardeep S., De Boer, Rudolf A., Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail, Lam, Carolyn S.P., Martinez, Felipe A., Shah, Sanjiv Jayendra, Desai, Akshay S., Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
LEFT ventricular hypertrophy , *HEART failure patients , *DAPAGLIFLOZIN - Published
- 2024
- Full Text
- View/download PDF
20. Incidence and Outcomes of Pneumonia in Patients With Heart Failure.
- Author
-
Shen, Li, Jhund, Pardeep S., Anand, Inder S., Bhatt, Ankeet S., Desai, Akshay S., Maggioni, Aldo P., Martinez, Felipe A., Pfeffer, Marc A., Rizkala, Adel R., Rouleau, Jean L., Swedberg, Karl, Vaduganathan, Muthiah, Vardeny, Orly, van Veldhuisen, Dirk J., Zannad, Faiez, Zile, Michael R., Packer, Milton, Solomon, Scott D., and McMurray, John J.V.
- Subjects
- *
HEART failure patients , *HEART failure , *ACE inhibitors , *PNEUMONIA , *ANGIOTENSIN receptors , *PNEUMONIA diagnosis , *RESEARCH , *RESEARCH methodology , *PROTEOLYTIC enzymes , *RETROSPECTIVE studies , *DISEASE incidence , *MEDICAL cooperation , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *BLIND experiment , *RESEARCH funding , *LONGITUDINAL method - Abstract
Background: The incidence of pneumonia and subsequent outcomes has not been compared in patients with heart failure and reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).Objectives: This study aimed to examine the rate and impact of pneumonia in the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) and PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in Heart Failure with Preserved Ejection Fraction) trials.Methods: The authors analyzed the incidence of investigator-reported pneumonia and the rates of HF hospitalization, cardiovascular death, and all-cause death before and after the occurrence of pneumonia, and estimated risk after the first occurrence of pneumonia in unadjusted and adjusted analyses (the latter including N-terminal pro-B-type natriuretic peptide).Results: In PARADIGM-HF, 528 patients (6.3%) developed pneumonia after randomization, giving an incidence rate of 29 (95% CI: 27 to 32) per 1,000 patient-years. In PARAGON-HF, 510 patients (10.6%) developed pneumonia, giving an incidence rate of 39 (95% CI: 36 to 42) per 1,000 patient-years. The subsequent risk of all trial outcomes was elevated after the occurrence of pneumonia. In PARADIGM-HF, the adjusted hazard ratio (HR) for the risk of death from any cause was 4.34 (95% CI: 3.73 to 5.05). The corresponding adjusted HR in PARAGON-HF was 3.76 (95% CI: 3.09 to 4.58).Conclusions: The incidence of pneumonia was high in patients with HF, especially HFpEF, at around 3 times the expected rate. A first episode of pneumonia was associated with 4-fold higher mortality. (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF], NCT01035255; Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ARB [Angiotensin Receptor Blocker] Global Outcomes in Heart Failure With Preserved Ejection Fraction [PARAGON-HF], NCT01920711). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
21. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
- Author
-
Zile, Michael R., O'Meara, Eileen, Claggett, Brian, Prescott, Margaret F., Solomon, Scott D., Swedberg, Karl, Packer, Milton, McMurray, John J.V., Shi, Victor, Lefkowitz, Martin, and Rouleau, Jean
- Subjects
- *
MATRIX metalloproteinase inhibitors , *EXTRACELLULAR matrix , *HEART development , *BIOMARKERS , *HEART failure patients , *AMINOBUTYRIC acid , *ACE inhibitors , *EXTRACELLULAR space , *HEART failure , *HETEROCYCLIC compounds , *HOSPITAL care , *LONGITUDINAL method , *STATISTICAL sampling , *RANDOMIZED controlled trials , *ANGIOTENSIN receptors , *STROKE volume (Cardiac output) , *ENALAPRIL - Abstract
Background: Myocardial fibrosis is an important pathophysiological mechanism underlying the development of heart failure (HF). Given the biochemical targets of sacubitril/valsartan, we hypothesized that circulating biomarkers reflecting the mechanisms that determine extracellular matrix (ECM) homeostasis, including collagen synthesis, processing, and degradation, are altered by sacubitril/valsartan in comparison to enalapril.Objectives: The purpose of this study was to examine the effects of sacubitril/valsartan on biomarkers of ECM homeostasis and the association between the rate of primary composite outcome (cardiovascular death or HF hospitalization) and these biomarkers.Methods: Biomarkers at baseline (n = 2,067) and both baseline and 8 months after randomization (n = 1,776) included aldosterone, soluble ST2 (sST2), tissue inhibitor of matrix metalloproteinase (TIMP)-1, matrix metalloproteinase (MMP)-2, MMP-9, Galectin-3 (Gal-3), N-terminal propeptide of collagen I (PINP), and N-terminal propeptide of collagen III (PIIINP). The effects of sacubitril/valsartan on biomarkers were compared with enalapril. Baseline biomarker values and changes from baseline to 8 months were related to primary outcome.Results: At baseline, the profibrotic biomarkers aldosterone, sST2, TIMP-1, Gal-3, PINP, and PIIINP were higher, and biomarkers associated with collagen degradation, MMP-2 and -9, were lower than published referent control values. Eight months after randomization, aldosterone, sST2, TIMP-1, MMP-9, PINP, and PIIINP had decreased more in the sacubitril/valsartan than enalapril group. At baseline, higher values of sST-2, TIMP-1, and PIIINP were associated with higher primary outcome rates. Changes from baseline to 8 months in sST-2 and TIMP-1 were associated with change in outcomes.Conclusions: Biomarkers associated with profibrotic signaling are altered in HF with reduced ejection fraction, sacubitril/valsartan significantly decreased many of these biomarkers, and these biomarkers have important prognostic value. These findings suggest that sacubitril/valsartan may reduce profibrotic signaling, which may contribute to the improved outcomes. (This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure [PARADIGM-HF]; NCT01035255). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
22. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.
- Author
-
Mogensen, Ulrik M., Jhund, Pardeep S., Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., Køber, Lars, McMurray, John J.V., and PARADIGM-HF and ATMOSPHERE Investigators and Committees
- Subjects
- *
ATRIAL fibrillation , *HEART failure patients , *MEDICAL statistics , *HOSPITAL care , *HEART disease related mortality , *ATRIAL fibrillation diagnosis , *HEART physiology , *LEFT heart ventricle , *COMPARATIVE studies , *HEART failure , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *RISK assessment , *SURVIVAL , *WORLD health , *EVALUATION research , *RANDOMIZED controlled trials , *STROKE volume (Cardiac output) , *DISEASE complications - Abstract
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown.Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 recent large trials in patients with HF with reduced ejection fraction.Methods: The study analyzed patients in the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) and ATMOSPHERE (Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure) trials. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for outcomes related to AF type.Results: Of 15,415 patients, 5,481 (35.6%) had a history of AF at randomization, and of these, 1,645 (30.0%) had paroxysmal AF. Compared with patients without AF, patients with paroxysmal AF at randomization had a higher risk of the primary composite endpoint of cardiovascular death or HF hospitalization (HR: 1.20; 95% confidence interval [CI]: 1.09 to 1.32; p < 0.001), HF hospitalization (HR: 1.34; 95% CI: 1.19 to 1.51; p < 0.001), and stroke (HR: 1.34; 95% CI: 1.02 to 1.76; p = 0.037), whereas the corresponding risks in patients with persistent or permanent AF were not elevated. Neither type of AF was associated with higher mortality. New onset AF was associated with the greatest risk of adverse outcomes: primary endpoint (HR: 2.21; 95% CI: 1.80 to 2.71), HF hospitalization (HR: 2.11; 95% CI: 1.58 to 2.81), stroke (HR: 2.20; 95% CI: 1.25 to 3.88), and all-cause mortality (HR: 2.26; 95% CI: 1.86 to 2.74), all p values < 0.001, compared with patients without AF. Anticoagulants were used less often in patients with paroxysmal (53%) and new onset (16%) AF than in patients with persistent or permanent AF (71%).Conclusions: Among HF patients with a history of AF, those with paroxysmal AF were at greater risk of HF hospitalization and stroke than were patients with persistent or permanent AF, underlining the importance of anticoagulant therapy. New onset AF was associated with increased risk of all outcomes. (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255) (Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure [ATMOSPHERE]; NCT00853658). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
23. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL.
- Author
-
Berg, David, Docherty, Kieran F., Talebi, Atefeh, Sattar, Naveed, Jarolim, Petr, Welsh, Paul, Jhund, Pardeep, Anand, Inderjit S., De Boer, Rudolf A., Kosiborod, Mikhail, Kober, Lars, Martinez, Felipe A., O'Meara, Eileen, Ponikowski, Piotr, Schou, Morten, Solomon, Scott D., Hammarstedt, Ann, Langkilde, Anna Maria, McMurray, John J.V., and Sabatine, Marc Steven
- Subjects
- *
HEART failure patients , *VENTRICULAR ejection fraction , *TREATMENT effectiveness , *DAPAGLIFLOZIN - Published
- 2023
- Full Text
- View/download PDF
24. DECLINE IN ESTIMATED GLOMERULAR FILTRATION RATE FOLLOWING SACUBITRIL/VALSARTAN INITIATION IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM PARAGON-HF AND PARADIGM-HF.
- Author
-
Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian, Causland, Finnian Mc, Rouleau, Jean L., Zile, Michael R., Packer, Milton, Pfeffer, Marc A., Lefkowitz, Martin, McMurray, John J.V., and Solomon, Scott D.
- Subjects
- *
GLOMERULAR filtration rate , *HEART failure patients , *ENTRESTO , *VALSARTAN - Published
- 2023
- Full Text
- View/download PDF
25. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial.
- Author
-
Abdul-Rahim, Azmil H., MacIsaac, Rachael L., Jhund, Pardeep S., Petrie, Mark C., Lees, Kennedy R., and McMurray, John J.V.
- Subjects
- *
DIGOXIN , *DRUG efficacy , *MEDICATION safety , *HEART failure patients , *DIABETES , *CLINICAL trials - Abstract
Background Digoxin is recommended in symptomatic heart failure patients with reduced ejection fraction (HF-REF) in sinus rhythm and refractory to other evidence-based therapy. Although HF-REF patients with diabetes have worse functional status than those without, the effects of digoxin have not been specifically evaluated according to diabetes status. Methods We examined the efficacy and safety of digoxin in HF-REF patients with and without diabetes in the Digitalis Investigation Group trial. Mortality from all-cause, cardiovascular (CV) causes and heart failure (HF), along with HF hospitalisation and suspected digoxin toxicity were analyzed according to diabetes status and randomised treatment assignment. Results Of the 6800 patients, those with diabetes (n = 1933) were older, more often women, had worse clinical status and more co-morbidity than those without diabetes. All-cause and CV mortality were higher in patients with diabetes than in those without and digoxin did not reduce mortality in either sub-group. The rate of HF hospitalization (per 100 person-years) in patients with diabetes was higher than in those without and was reduced by digoxin in both patient groups: diabetes – placebo 20.5 and digoxin 16.0 (HR 0.79, 95% CI: 0.68–0.91); no diabetes – placebo 12.7 and digoxin 8.7 (HR 0.69, 0.62–0.77); interaction p = 0.14. Suspected digoxin toxicity in patients randomised to digoxin was more common among patients with diabetes than without (6.5% versus 5.8%), as was hospitalisation for digoxin toxicity (1.4% versus 0.8%). Conclusion Added to an ACE inhibitor, digoxin reduced HF hospitalisation in HF-REF patients with and without diabetes without a substantial risk of toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF.
- Author
-
van Diepen, Sean, Podder, Mohua, Hernandez, Adrian F., Westerhout, Cynthia M., Armstong, Paul W., McMurray, John J.V., Eapen, Zubin J., Califf, Robert M., Starling, Randall C., O'Connor, Christopher M., and Ezekowitz, Justin A.
- Subjects
- *
HEART failure patients , *NESIRITIDE , *INTENSIVE care units , *HEALTH outcome assessment , *HOSPITAL care , *REGRESSION analysis - Abstract
Background: Little is known about global patterns of critical care unit (CCU) care and the relationship with outcomes in patients with acute decompensated heart failure (ADHF). Whether a ward or a CCU admission is associated with better outcomes is unclear. Methods: Patients in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial were initially hospitalized in a ward or CCU (coronary or intensive care unit). Sites were geographically classified: Asia-Pacific (AP), Central Europe (CE), Latin America (LA), North America (NA), and Western-Europe (WE). The primary outcome of 30-day all-cause mortality or all-cause hospital readmission was adjusted using a two-stage multivariable logistic regression model with a generalized estimated equation that took sites within each country as a nested random factor. Results: Overall, 1944 (38.2%) patients were admitted to a CCU and 3150 (61.8%) to a ward, and this varied by region: 50.6% AP, 63.3% CE, 60.7% WE, 22.1% LA, and 28.6% NA. The 30-day death or readmission rate was 15.2% in ward patients and 17.0% in CCU patients (risk-adjusted Odds Ratio [OR] 1.44: 95% CI, 1.14–1.82). Compared with CCU patients in NA (24.1% 30-day event rate), the primary outcomes were: AP (10.4%, Odds Ratio [OR] 0.63; 95% confidence Interval [CI], 0.35 to 1.15), CE (10.4%, OR 0.56: 95% CI, 0.31 to 1.02), LA (22.4%, OR 0.60: 95% CI, 0.11 to 3.32), and WE (11.2%, OR 0.63, 95% CI, 0.25 to 1.56). No regional differences in 30-day mortality were observed; however, 30-day readmission rates were highest in NA sites. Conclusions: Management of patients with ADHF varies significantly, and after adjustment, CCU care was associated with higher risk of early mortality, not explained by international differences. These findings may help to improve the early decisions regarding risk stratification of patients hospitalized with ADHF. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. The association between meteorological events and acute heart failure: New insights from ASCEND-HF.
- Author
-
Das, Debraj, Bakal, Jeffery A., Westerhout, Cynthia M., Hernandez, Adrian F., O'Connor, Christopher M., Atar, Dan, McMurray, John J.V., Armstrong, Paul W., and Ezekowitz, Justin A.
- Subjects
- *
HEART failure , *HEART failure patients , *DISEASE prevalence , *COMPARATIVE studies , *BIOCLIMATOLOGY , *CLINICAL trials , *DIAGNOSIS - Abstract
Introduction: Given the rising prevalence of heart failure (HF), our objective is to explore the relationships between meteorological events and acute HF (AHF) globally. Methods: We used data from 30 countries participating in the ASCEND-HF trial. Parameters including temperature were normalized by location for the 37 days prior to the HF event. Meteorological events were classified as a change that occurred < 10% compared to baseline. The 7 days prior to the HF event was subdivided: T1: the day of and − 1 day; T2: 2 and 3 days; T3: 4 and 5 days; and T4: 6 and 7 days. Results are reported as ratios of observed to expected weather events at the time of AHF presentation. Results: From 7141 patients, median age was 67 (IQR 56–76) with 66% male patients and 60% of patients with ischemic cardiomyopathy. In T1, temperatures were warmer than expected with 10% fewer decreases in average [OR 0.91 95% CI (0.83–0.98)] and minimum [OR 0.90 95% CI (0.82–0.97)] temperature. In T2, temperatures were again warmer than expected with an excess number of increases in maximum [OR 1.18 95% CI (1.06–1.30)] and average [OR 1.21 95% CI (1.10–1.32)] temperature. In T4 temperatures were cooler than baseline with fewer increases [OR 0.84 95% CI (0.74–0.95)] in average temperature. Conclusions: Meteorological fluctuations appear most relevant in the 3 days (T1 and T2) prior to the HF hospitalization with temperature demonstrating a bidirectional relationship with AHF. Continued validation of biometeorological trends in HF will contribute to healthcare system planning globally. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
28. Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment.
- Author
-
Damman, Kevin, Perez, Ana C., Anand, Inder S., Komajda, Michel, McKelvie, Robert S., Zile, Michael R., Massie, Barrie, Carson, Peter E., and McMurray, John J.V.
- Subjects
- *
HEART failure patients , *ANGIOTENSIN receptors , *RENIN-angiotensin system , *GLOMERULAR filtration rate , *HEALTH outcome assessment - Abstract
Background Worsening renal function (WRF) associated with renin-angiotensin-aldosterone system (RAAS) inhibition does not confer excess risk in heart failure patients with reduced ejection fraction (HFrEF). Objectives The goal of this study was to investigate the relationship between WRF and outcomes in heart failure patients with preserved ejection fraction (HFpEF) and the interaction with RAAS blockade. Methods In 3,595 patients included in the I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction) trial, change in estimated glomerular filtration rate (eGFR) and development of WRF after initiation of irbesartan or placebo were examined. We examined the association between WRF and the first occurrence of cardiovascular death or heart failure hospitalization (primary outcome in this analysis) and the interaction with randomized treatment. Results Estimated GFR decreased early with irbesartan treatment and remained significantly lower than in the placebo group. WRF developed in 229 (6.4%) patients and occurred more frequently with irbesartan treatment (8% vs. 4%). Overall, WRF was associated with an increased risk of the primary outcome (adjusted hazard ratio [HR]: 1.43; 95% confidence interval [CI]: 1.10 to 1.85; p = 0.008). Although the risk related to WRF was greater in the irbesartan group (HR: 1.66; 95% CI: 1.21 to 2.28; p = 0.002) than with placebo (HR: 1.09; 95% CI: 0.66 to 1.79; p = 0.73), the interaction between treatment and WRF on outcome was not significant in an adjusted analysis. Conclusions The incidence of WRF in HFpEF was similar to that previously reported in HFrEF but more frequent with irbesartan than with placebo. WRF after initiation of irbesartan treatment in HFpEF was associated with excess risk, in contrast to WRF occurring with RAAS blockade in HFrEF. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency: Practical Considerations From Published Data.
- Author
-
Damman, Kevin, Tang, W.H. Wilson, Felker, G. Michael, Lassus, Johan, Zannad, Faiez, Krum, Henry, and McMurray, John J.V.
- Subjects
- *
HEART failure treatment , *KIDNEY failure , *CLINICAL trials , *HEART failure patients , *HEALTH outcome assessment , *COMPARATIVE studies , *THERAPEUTICS - Abstract
Chronic kidney disease (CKD) is increasingly prevalent in patients with chronic systolic heart failure. Therefore, evidence-based therapies are more and more being used in patients with some degree of renal dysfunction. However, most pivotal randomized clinical trials specifically excluded patients with (severe) renal dysfunction. The benefit of these evidence-based therapies in this high-risk patient group is largely unknown. This paper reviews data from randomized clinical trials in systolic heart failure and the interactions between baseline renal dysfunction and the effect of randomized treatment. It highlights that most evidence-based therapies show consistent outcome benefit in patients with moderate renal insufficiency (stage 3 CKD), whereas there are very scarce data on patients with severe (stage 4 to 5 CKD) renal insufficiency. If any, the outcome benefit might be even greater in stage 3 CKD compared with those with relatively preserved renal function. However, prescription of therapies should be individualized with consideration of possible harm and benefit, especially in those with stage 4 to 5 CKD where limited data are available. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
30. What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?
- Author
-
Campbell, Ross T., Jhund, Pardeep S., Castagno, Davide, Hawkins, Nathaniel M., Petrie, Mark C., and McMurray, John J.V.
- Subjects
- *
HEART failure patients , *ANGIOTENSIN converting enzyme , *HOSPITAL care , *HEART disease related mortality , *CLINICAL trials , *HEALTH outcome assessment , *DIABETES - Abstract
Examination of patients with reduced and preserved ejection fraction in the DIG (Digitalis Investigation Group) trials and the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) trials provides comparisons of outcomes in each of these types of heart failure. Comparison of the patients in these trials, along with the I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function Trial), with patients of similar age, sex distribution, and comorbidity in trials of hypertension, diabetes mellitus, angina pectoris, and atrial fibrillation provides even more interesting insights into the relation between phenotype and rates of death and heart failure hospitalization. The poor clinical outcomes in patients with heart failure and preserved ejection fraction do not seem easily explained on the basis of age, sex, comorbidity, blood pressure, or left ventricular structural remodeling but do seem to be explained by the presence of the syndrome of heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
31. Reply: Different Phenotype Characterization in PARAGON-HF: An Unresolved Puzzle in Patients With HFpEF.
- Author
-
Shah, Amil M., Cikes, Maja, Zile, Michael R., McMurray, John J.V., Solomon, Scott D., and PARAGON-HF Investigators
- Subjects
- *
WOMEN'S hospitals , *HEART failure patients , *COMPARATIVE studies , *ECHOCARDIOGRAPHY , *LEFT heart ventricle , *HEART physiology , *HEART failure , *RESEARCH methodology , *MEDICAL cooperation , *PATIENTS , *RESEARCH , *PHENOTYPES , *EVALUATION research , *STROKE volume (Cardiac output) - Published
- 2020
- Full Text
- View/download PDF
32. PROGNOSTIC IMPLICATIONS OF BASELINE AND FOLLOW-UP CARDIOVASCULAR PHYSICAL EXAMS IN A CONTEMPORARY TRIAL OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: PARADIGM-HF.
- Author
-
Selvaraj, Senthil, Claggett, Brian, Pozzi, Andrea, McMurray, John J.V., Jhund, Pardeep, Packer, Milton, Desai, Akshay S., Lewis, Eldrin F., Lefkowitz, Martin, Rouleau, Jean L., Shi, Victor, Zile, Michael R., Swedberg, Karl, and Solomon, Scott D.
- Subjects
- *
HEART failure , *HEART failure patients - Published
- 2019
- Full Text
- View/download PDF
33. 810-1 Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure.
- Author
-
Yusuf, Salim, Ostergren, Jan B, Gerstein, Hertzel, Pfeffer, Marc A, Swedberg, Karl, Granger, Chris B, and McMurray, John J.V
- Subjects
- *
NEOVASCULARIZATION , *ANGIOTENSIN-receptor blockers , *CANDESARTAN , *DIABETES prevention , *HEART failure patients - Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.